Diabetic Neuropathy Treatment Market Overview

The global diabetic neuropathy treatment market is slated to display a CAGR of 5.1% from 2022 to 2030 (forecast period). It can touch a value of USD 5.80 billion by 2025. High prevalence of the disorder is one of the biggest drivers of the market. Treatment of diabetic neuropathy is the second-biggest cause of disability, with close to 30-40% people living with the disorder globally. The large geriatric populace and the sedentary lifestyle are other drivers which can cause the disorder.

The increase noticed in the funding in research and development of novel treatment methods can bode favorably for the market growth. Awareness of new drugs and medications by patients can propel the market demand considerably.

Diabetic Neuropathy Treatment Market is one of the most common causes of neuropathy, a disease which damages the nerves. It is commonly seen in diabetics, with a large section of patient suffering from loss of sensation and weakness. The global diabetic neuropathy treatment market report by Market Research Future (MRFR) has been analyzed by respected research analysts and compiled with the collaboration of industry experts and subject matter experts.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/8359

Diabetic Neuropathy Treatment Market Segmentation

The global diabetic neuropathy treatment market is segmented by disorder, treatment, and end-user.

By disorder, it is segmented into peripheral, autonomic, proximal, and focal. The peripheral segment had the largest market share due to the chances of the disorder affecting women more than men.

By treatment, it is segmented into drugs, transcutaneous electrical nerve stimulation (TENS), and others. Drugs are touted to be the fastest growing segment of the market during the forecast timespan. This can be attributed to the large approval of drugs by regulatory agencies for the treatment of diabetic neuropathy. On the other hand, the TENS segment can experience rapid growth due to being the preferred mode for treatment by adults with the disorder.

By end-user, it is segmented into online pharmacy, retail pharmacy, hospitals & clinics, and others. Hospitals and clinics are expected to retain their position till 2025 due to the establishments being the primary unit for treatment. Awareness of the disorder combined with availability of treatment and medicines available at these centers can drive the segment growth.

Diabetic Neuropathy Treatment Market Regional Analysis

North America leads the global diabetic nephropathy market, heading with the presence of a vast patient population, well-developed healthcare sectors, and industry leaders in the region. The prevalence of diabetic neuropathy & various kidney diseases is quite high in North America. Also, the region has state-of-the-art healthcare infrastructure, which, as a result, impacts the market growth positively.

Additionally, the increasing emphasis in the region for diagnosis and continuous monitoring of diabetes & high blood pressure, using advanced diagnostic tests and devices, substantiate the market growth. Furthermore, increasing funding support from the government and private companies to improve diabetes care in the region drives the growth of the diabetic nephropathy market in North America.

Europe stands second in the global diabetic nephropathy market due to the rising cases of diabetic neuropathy disorder.  Also, factors such as the government support that encourage the players to develop high-quality technologies for diabetes care and favorable reimbursement policies are driving the regional market growth, predominantly. Certainly, the resurging economy is playing a causal role in supporting the regional market growth, availing the best possible healthcare & increasing the per-capita healthcare expenditures. 

The Asia Pacific region is emerging as a promising market for diabetic nephropathy treatments. Factors such as the rapidly growing healthcare sector and awareness among individuals towards diabetic care and the advantages & availability of therapeutics drive the growth of the diabetic nephropathy market in the region. Besides, the growing prevalence of diabetes and kidney disease, alongside the ever-increasing geriatric population, acts as a major driving force for the regional market growth.

Competition Outlook

Hoffmann-La Roche Ltd, Astellas Pharma Inc, Abbott Laboratories, MEDA Pharma GmBH & Co. KG, Glenmark Pharmaceuticals Limited, Pfizer Inc, GlaxoSmithKline Plc, Johnson & Johnson, Lupin Limited, Eli Lilly and Company, Depomed, Inc., and others are noteworthy participants of the global diabetic neuropathy treatment market. Collaborations and new product launches are strategies to be watched for during the forecast period.

Industry News

Local centers are using drug-free methods to treat patients in order to alleviate the pain on taxpayers. The American College of Physicians has recommended therapies such as spinal manipulation, photobiomodulation, and multidisciplinary rehabilitation for the treatment of nerves damaged due to the disease.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/diabetic-neuropathy-treatment-market-8359

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com